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EVALUATING THE THERAPEUTIC EFFICACY OF GRB2 INHIBITION IN
OVARIAN MALIGNANCIES

Olivia D. Lara, M.D.
Advisory Professor: Anil K. Sood, M.D.

Abstract
Purpose: Adaptor proteins such as growth factor receptor-bound protein-2 (Grb2) play
important roles in cancer cell signaling. In the present study, we examined the biological
effects of liposomal antisense oligodeoxynucleotide that blocks Grb2 expression (LGrb2) in ovarian cancer models.
Experimental Design: Murine orthotopic models of ovarian cancer (OVCAR5 and
SKOV3ip1) were used to study the biological effects of L-Grb2 on tumor growth. In vitro
experiments (cell viability assay, Western blot analysis, siRNA transfection, and reverse
phase protein array) were carried out to elucidate the mechanism and potential predictors
of tumor response to L-Grb2.
Results: Treatment with L-Grb2 decreased tumor growth and metastasis in orthotopic
models of ovarian cancer (OVCAR5, SKOV3ip1) by reducing angiogenesis and
increasing apoptosis at a dose of 15 mg/kg with no effect on mouse body weight.
Treatment with L-Grb2 and paclitaxel led to the greatest decrease in tumor weight
(mean± SEM, 0.17 g ± 0.10 g) compared with that in control mice (0.99 g ± 0.35 g). We
also observed a reduction in tumor burden after treatment with L-Grb2 and the anti-VEGF
antibody B-20 (86% decrease in tumor weight compared with that in controls). Ovarian
cancer cells with ErbB2 amplification (OVCAR8 and SKOV3ip1) were the most sensitive

iv

to Grb2 downregulation. Reverse phase protein array analysis identified significant
dysregulation of metabolites (LDHA, GAPDH, and TCA intermediates) in ovarian cancer
cells after Grb2 downregulation.
Conclusions: L-Grb2 has therapeutic efficacy in preclinical models of ovarian cancer.
These findings support the clinical development of L-Grb2 for treatment of cancer.
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1. Background and Introduction
1.1 Ovarian cancer statistics and standard of care
Ovarian cancer ranks among the most lethal types of malignancies of the female
reproductive system and comprises a molecularly diverse range of tumors. 9 In 2019,
there will be approximately 22,000 new cases ovarian cancer diagnosed and 14,000
ovarian cancer death in the United States. 1 A woman’s risk of ovarian cancer during her
lifetime is about 1 in 70, while her lifetime chance of dying from ovarian cancer is about
1 in 100.2 Histologically, ovarian tumors range from epithelial, sex cord-stromal and germ
cell origin. However the majority of ovarian cancers are of epithelial origin, of which high
grade serous carcinoma is the most common histologic subtype making up >70% of
ovarian carcinomas.3 The additional four subtypes of epithelial cancers occur at lower
frequency and have more favorable prognosis.4 These include endometrioid, clear cell,
mucinous and low-grade serous carcinomas which collectively account for approximately
25% of the remaining ovarian carcinomas.3 Each histologic subtype of ovarian cancer
represents clinically and molecularly different tumors with unique origin precursors.

5,6

For example high grade serous carcinoma is thought to originate from serous tubal
intraepithelial carcinoma (STIC), an early pre-invasive lesion in the fallopian tube,7 while
endometrioid and clear cell carcinomas may develop from endometriosis.8

In addition to the cellular and molecular differences between histological subtypes,
ovarian cancer often presents at a late stage making treatment challenging. Early ovarian
cancer often has no obvious symptoms, with most women reporting vague, nonspecific
symptoms. The most common sign of ovarian cancer is abdominal swelling, which occurs
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at the late stages of cancer development. Only 20% of patients with ovarian cancer are
diagnosed at an early stage, for which 5 year survival reaches 90%. 9 However the
majority of patients present with higher stage disease for which 5 year overall survival is
a dismal 29%. (Table 1).

Table 1. Ovarian Cancer stage and five year overall survival

9,10

FIGO Stage

Criteria

5-year survival

IA

Tumor limited to one ovary or fallopian tube

89.6

IB

Tumor limited to both ovaries or fallopian tubes

86.1

IC

Tumor limited to one or both ovaries or fallopian 83.4
tubes with surgical spill/capsule rupture or malignant
ascites

IIA

Extension and/or implants on the uterus and/or 70.7
fallopian tubes and/or ovaries

IIB

Extension to and/or implants on other pelvic tissues

65.5

IIIA

Microscopic extrapelvic peritoneal involvement +/- 46.7
retroperitoneal lymph nodes

IIIB

Macroscopic peritoneal metastasis 2cm or less

41.5

IIIC

Macroscopic peritoneal metastasis more than 2cm

32.5

IV

Distant metastasis including pleural effusion with 18.6
positive cytology
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Surgical staging and cytoreduction followed by adjuvant chemotherapy is the
management approach used for most patients with ovarian carcinoma. 11 Surgical staging
entails total hysterectomy with bilateral salpingo-oophorectomy, pelvic and paraaortic
lymph node dissection, omentectomy, and assessment of abdominal cavity with
biopsies.12 Cytoreductive surgery is performed with the goal to remove all gross residual
disease.13 The ability to remove macroscopic disease with cytoreductive surgery
correlates with improvements in survival.14 In patients with early stage ovarian carcinoma
surgery is followed by adjuvant taxane and platinum based chemotherapy regimens.
Despite initial response to therapy, the majority of patients will relapse and require
retreatment. In the relapse setting there are several treatment options available, but the
ideal treatment option is not known. These include cytotoxic drugs, doxorubicin,
gemcitabine, and topotecan, as well as new agents such as bevacizumab and poly-ADP
ribose polymerase (PARP) inhibitors. Improvements in surgical technique and the
development of targeted therapies have led to a decreasing incidence rate in ovarian
carcinoma,4 however the overall cure rate remains 30%.15 Given the clinical and genetic
heterogeneity of ovarian cancer, prolonging survival might be achieved by targeting
cellular and molecular mechanisms important to tumor pathogenesis.

1.2 Molecular Alterations in Ovarian Cancer
While changes in chemotherapy regimens and the addition of bevacizumab and PARP
inhibitor therapies have considerably improved outcomes, they appear to have reached
their therapeutic ceiling. Additionally PARP inhibitors have primarily demonstrated
efficacy in recurrent ovarian cancer patients with germline BRCA1/2 mutations, or
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deficiencies in homologous recombination.16 Unfortunately ovarian cancer lags behind a
number of solid malignancies in the number of therapies available. 17 The identification of
potential molecular targets and novel therapies are desperately needed to prolong
survival especially in high grade ovarian carcinoma. In order to develop such therapies,
we must better understand genomic abnormalities that influence pathology, and
constitute therapeutic targets.

Currently we know mutation and loss of TP53 function, and copy number alterations are
the most frequent observed abnormality in high grade serous ovarian cancers. 18,19 While
the centrality of TP53 to ovarian cancers has been established, clinically restoring p53
function has not proven to be of clinical benefit.20 Other somatic mutations found to be
significantly altered in ovarian carcinoma include BRCA1, BRCA2, RB1, CDK12, and
NF1.19 The high prevalence of BRCA pathway alterations in ovarian carcinoma have
resulted in the use of PARP inhibitors with corresponding good responses. An additional
challenge is the heterogeneity within histologic subtypes of ovarian cancer (Table 2).15
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Table 2. Molecular Features of epithelial ovarian tumors
Histology

Mutation

Low-grade serous carcinoma

KRAS and/or BRAF

Low-grade

endometrioid CTNNB1, PTEN, PIK3CA, microsatellite

carcinoma

instability

Mucinous carcinoma

KRAS, TP53

Clear cell carcinoma

PTEN, PIK3CA

High-grade serous carcinoma

TP53 (80%), BRCA1

High-grade

endometrioid TP53, BRCA1, PIK3CA

carcinoma

Published studies have integrated genomic data to analyze the most frequently disturbed
cancer-associated pathways according to mutations, changes in gene expression and
copy number changes. Mutations in RAS/RAF/MAPK pathway are found in more than
50% of low grade serous carcinomas while PI3K/AKT/mTOR signaling pathway is altered
in 70% of high grade serous carcinomas.

21-24

These alterations suggest that targeting

components of either pathway may represent a useful strategy in ovarian cancer.

1.3 Targeting Therapies in Development
MAPK and PI3K/AKT/mTOR cell signaling pathways play important roles in cell growth,
proliferation, and survival. Mutations of these pathways is frequently implicated in a
number of solid tumors, and the development of inhibitors has already been undertaken
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and can potentially be translated to ovarian carcinoma. 25 For instance, up to 35% of
patients with low grade serous carcinoma will harbor V600E BRAF mutations, usually
confined to early stage disease.26 Administration of debrafenib and trametinib
combination therapy, BRAF and MEK1/2 inhibitor therapy, yielded positive results in a
patient with low-grade serous carcinoma. 27 RO5126766 is a first-in-class dual MEK/RAF
inhibitor currently in early development for advanced solid tumors. RO5126766 was
assessed in a phase 1 study of solid tumors including ovarian cancer (n=6). A modest
reduction in tumor size was seen in 40% of patients across tumor types.28 Simultaneous
inhibition of both pathways with MEK1/2 inhibitor, pimasertib, and dual PI3K/mTOR
inhibitor, SAR245409, suggested signs of clinical activity in three patients with low-grade
ovarian carcinoma in a phase 1 clinical trial. 29

Additional therapeutics in development include inhibitors of EGFR and ErbB2 (HER2)
which are required for activation of MAPK and PI3K/AKT pathways. Gefitinib (EGFR
inhibitor) yielded modest efficacy in advance solid tumors including ovarian carcinoma.30
The addition of EGFR inhibitor, erlotinib, to paclitaxel and carboplatin also appeared to
be favorable to paclitaxel and carboplatin only in patients with resected disease. 31 ErbB2
is overexpressed in 11% of ovarian cancers. Trastuzumab, anti-HER2 antibody, yielded
an overall response of 7.3% with one complete and two partial responses in patients with
recurrent or refractory ovarian carcinoma.

32

While current therapies are promising for ovarian cancer patients, a closer look at these
cancer signaling pathways may reveal additional therapeutic targets. Taking a closer
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look at MAPK and PI3K/AKT/mTOR pathways common signaling activation through
receptor tyrosine kinases (RTKs) and growth factor receptors is noted (Figure 1). Upon
activation, either by ligand binding or protein overexpression, dimerization and
stabilization of RTKs occurs, resulting in stimulation of tyrosine kinase activates and
auto-phosphorylation on tyrosine residues. 33,34 Phosphotyrosine residues are then used
as docking sites for various proteins. One such protein is growth factor receptor-bound
protein-2 (Grb2). Adaptor proteins such as Grb2 are essential for signal propagation after
receptor tyrosine kinase activation.35 Grb2 is a 25kDa adaptor protein which uses its SH2
domain to bind to phosphotyrosine residues found in RTKs (EGFR, ErbB2, VEGF) and
its SH3 domains to bind to proline-rich motifs, such as those found in guanine nucleotide
exchange factor Son of Sevenless (SOS).36-39 SOS activation leads to activation of RAS
ultimately increasing RAF, MEK and ERK activity.40,41 Besides guanine nucleotide
exchange factors, Grb2 has been demonstrated to use its SH3 domain to bind to prolinerich proteins such as phosphatidylinositol 3-kinase (PI3K). PI3K activity can also occur
due to activating mutations of RAS showing the crosstalk that exists between pathways.
Therefore targeting one pathway may result in activation of another as a compensatory
mechanism. Because of Grb2’s central location, and crucial involvement in transducing
the signals of oncogenic tyrosine kinases to downstream mediators it is an attractive
therapeutic target.
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Figure 1. Overview of RTK signaling

1.4 Nucleic-Acid based therapeutics
Key adaptor proteins, such as Grb2, have previously thought to be undruggable
molecular targets. Actionable targets have often been proteins with an enzymatically
active site to which a small molecule could bind, however the ability to target previously
undruggable targets is evolving. Small molecule inhibitors rely on intracellular targets,
or antibodies to inhibit growth factors, cell surface receptors or cytokines 42,43. More
recently the use of nucleic acid based therapeutics, which allows for the regulation of
gene expression, has been employed to inhibit elusive targets

44,45.

Nucleic-acid based

therapeutics is a process in which RNA molecules or antisense oligonucleotides (ASOs)
inhibit gene expression or translation by neutralizing targeted mRNA molecules. 46,47 A
double-stranded RNA molecule silences gene expression by inducing degradation of a
8

complimentary mRNA. Small interfering RNAs (siRNA), and antisense oligonucleotides
(ASO) are the most commonly used methods of gene silencing (Figure 2).

Figure 2. Methods of nucleic-acid based interference

SiRNA interact with RNA-induced silencing complex to block and neutralize the target
mRNA.48,49 Larger siRNAs require processing by ribonuclease III-like DICER enzyme.
DNA/RNA-like ASOs bind to RNA through complementary base pair interactions. After
crossing the cell membrane ASOs target mRNA direction, in the nucleus or cytosol, thus
blocking and neutralizing the targeted mRNAs. Both siRNA and ASOs provide specific
and efficient knockdown of gene expression. Comparisons between siRNA and ASO in
in vitro assays have shown that siRNA leads to quicker and more durable gene
knockdown compared to ASO.50 This may translate to lower doses with less frequency
9

in patients. Both siRNA and ASOs have been associated with nonspecific toxicity at high
doses in vivo.51 However, the antisense approach is a mature method with proven
efficacy in human trials. SiRNA remains a novel technology with increase costs, for which
new problems may be encountered.

RNA is rapidly degraded in circulation due to RNAases and requires formulations into
nanoparticles to carry them to their target tissues (Figure 3).52,53 Liposomes have been
widely studied and utilized for targeted drug delivery.52 The ability of liposomes to interact
with cells and aid in drug delivery strongly depends on the density and charge on the
liposome surface. Both cationic (positively charged) and anionic (negatively charged)
liposomes have shown encouraging results in in vitro and in vivo experiments. However
due to their electrostatic properties they are can cause a number of side effects including
rapid uptake by reticuloendothelial system (RES), leading to cytokine storm and acute
pulmonary toxicity.54-56 Because of their positive charge, cationic liposomes are less
likely to be taken up by cells as well. Neutral liposomes (no surface charge) produce
less side effects, but lack stability leading to increased aggregation. 57,58 Overall
liposomes provide a valid method of delivery of synthetic siRNA and ASOs.
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Figure 3. Liposome delivery system
Here we focused on testing the anticancer effects of ASO that blocks Grb2 protein
expression (L-Grb2) incorporated into a neutral liposome. The high prevalence of
molecular alterations in the MAPK and PI3K/AKT/mTOR pathways in ovarian carcinoma,
combined with this novel therapeutic system represents an important therapeutic
opportunity.
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2. Hypothesis and Specific Aims

2.1 Hypothesis: The central goal of this project was to elucidate the role of
Grb2 in ovarian malignancies. Specifically we evaluated the efficacy of Grb2
inhibition in ovarian tumor models and in vitro experiments to establish rationale
for the use of L-Grb2 as an ovarian cancer therapeutic. We hypothesized Grb2
inhibition will reduce tumor growth by interfering with rec eptor tyrosine kinase
signaling

(Ras/Raf/MAPK

and

PI3K/AKT/mTOR

pathways)

critical

to

carcinogenesis.
2.2 Specific Aim 1: To determine the biological efficacy of L-Grb2 in
ovarian tumor models and in vitro assays
2.3 Specific Aim 2: To determine the mechanisms responsible for
biological effects of Grb2 downregulation and identify potential predictors
of response to L-Grb2 therapy.
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3. Materials and Methods
3.1 Cell line maintenance and siRNA transfection
The ovarian cancer cell lines OVCAR8, HeyA8, A2780ip1, and SKOV3ip1 were
maintained in RPMI 1640 medium supplemented with 10% FBS and 0.1% gentamicin
sulfate (Gemini Bioproducts). OVCAR5 ovarian cells and KLE uterine cells were
maintained in Dulbecco’s modified Eagle’s medium with 10% FBS and 0.1% gentamicin
sulfate. RF-24 endothelial cells were maintained in Dulbecco’s modified Eagle’s medium
(MEM) supplemented with pyruvate, amino acids, and penicillin/streptomycin. Uterine
cancer cell lines MFE319, Ishikawa were maintained in MEM supplemented with 10%
FBS and 0.1% gentamicin sulfate Hec1a uterine cells were maintained in MCoy’s 5A
supplemented with 10% FBS and 0.1% gentamicin sulfate. All of these cells were
cultured at 37°C using a 5% CO2 incubator. Cell line authentication was performed by
the Characterized Cell Line Core at The University of Texas MD Anderson Cancer
Center. Mycoplasma testing of the cells was performed using an ATCC Universal
Mycoplasma Detection Kit. All in vitro experiments were conducted with 80% confluent
cultures and fewer than 20 passages. Ovarian cancer cells were transfected with Grb2
siRNA or control siRNA. All siRNA sequences were purchased from Sigma-Aldrich
(SASI_Hs01_00129586). Cells were seeded in six-well plates at a density that yielded
50-60% confluence after 24 hours of platting (100,000 to 150,000 cells/well). The next
day, 1.3 L (100 nm) of siGrb2 sequences were mixed at a 1:3 ratio with Lipofectamine
2000 (lot #1774775; Invitrogen) prepared in serum-free medium for 20 minutes. The
transfection complex was added to cells with serum-free medium. Cells were incubated
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with the siRNA/Lipofectamine 2000 complex for 4 hours in a 37°C, 5% CO 2 incubator
and refreshed with complete medium after 4 hours. Cells were then harvested for
Western blot analysis to verify Grb2 knockdown. For transfection in 96-well plates, cells
were plated at a density of 5,000-7,000 cells per well in technical replicates in six wells
per siRNA sequence. The next day, cells were transfected with 0.21 L of siRNA in
serum-free media and incubated for 4 hours in a tissue culture incubator as described
above. Cells were then re-fed with complete media and subjected to alamarBlue viability
assays.

3.2 Cell viability assays
Cell viability assays were performed by testing cells’ ability to reduce alamarBlue
(Bio-Rad). Ovarian cancer cell lines were seeded in a 96-well plate and transfected the
next day with increasing concentrations of siControl or siGrb2. After 72 hours, cells were
incubated with 0.10% alamarBlue for 4 hours at 37°C. The absorbance at 540 nm was
then recorded.

3.3 Immunoblotting
After siRNA transfection, cells were harvested and lysed with RIPA buffer (1%
Triton X-100, 25 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate)
supplemented with fresh protease and phosphatase inhibitors (TC260670 and
TJ272575; Thermo Fisher Scientific). Protein quantification was performed using a BCA
Protein Assay Kit (#23235; Thermo Fisher Scientific) following the manufacturer’s
protocol. Thirty micrograms of cell lysates was loaded onto SDS-PAGE gels. After
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separation, proteins were transferred to nitrocellulose membranes and blocked with 5%
nonfat dry milk (#AB10109-0100; AmericanBio) in TBS-T (0.1% Tween-20) for 1 hour at
room temperature. After blocking, indicated antibodies diluted in 5% milk in TBS-T were
placed on membrane overnight at 4°C. The next day, the membranes were washed three
times with TBS-T for 10 minutes with light agitation. Afterward, a species-specific
secondary antibody was placed on membrane for 2 hours at room temperature. The
membranes were then washed three times in TBS-T and finally developed using Western
Lightning Plus-ECL (#NEL105001EA; PerkinElmer) on X-ray film (#F-BX57; Phoenix
Research Products). For re-probing of Western blots, membranes were stripped using
Restore PLUS Western Blot Stripping Buffer (#46430; Thermo Fisher Scientific), reblocked with 5% milk in TBS-T, and incubated with a primary antibody. The antibody
dilutions were as follows: anti-Grb2, 1:1000 (#3972; Cell Signaling Technology); antiErbB2, 1:100 (2242S; Cell Signaling Technology), anti-vinculin, 1:2000 (V9131, lot
#118M4777V; Sigma), anti--actin, 1:2000 (127M4866V; Sigma), anti-GAPDH, 1:1000
(5174, Cell Signaling Technology), anti-LDHA, 1:1000 (3582, Cell Signaling
Technology), anti-c-MYC, 1:1000 (5605, Cell Signaling Technology) and anti-SOD2
(13141, Cell Signaling Technology).

3.4 Murine orthotopic models of ovarian carcinoma
All mice used in the study were 8-12 weeks old at the beginning of the
experiments. For all animal experiments, cells were harvested using trypsin-EDTA,
neutralized with FBS-containing media, and re-suspended in Hank’s balanced salt
solution (Gibco) before injection into the mice. To generate ovarian carcinoma models,

15

OVCAR5 cells (1 x 106 in 200 L of Hank’s balanced salt solution) and SKOV3ip1 cells
(1 x 106 in 200 L of Hank’s balanced salt solution) were injected into mice
intraperitoneally. Mice were given paclitaxel (35ug per mouse) once weekly or B-20-4.1.1
(VEGF:5563, Lot #71943-30, Genentech) (6.25 mg/kg) twice weekly via intraperitoneal
injection. Furthermore, an empty DOPC liposome or L-Grb2 (BP1001-002; Bio-Path
Holdings, Inc.) was injected intravenously via the tail vein at a dose of 15 mg/kg twice
weekly. Once mice in any group became moribund, all mice were sacrificed. All animal
studies were approved by MD Anderson IACUC committee. Tumors were harvested from
the mice and weighed, and the numbers of nodules and tumor weights were recorded.
Tumor tissue was preserved and fixed in formalin for paraffin embedding, frozen in
optimal cutting temperature medium to prepare frozen slides, or snap-frozen for lysate
preparation.

3.5 Immunohistochemistry
Harvested tumor samples were embedded in paraffin blocks and sectioned by the
MD Anderson Research Histology Core Laboratory. Paraffin-embedded tissue samples
were used to stain for Ki67 (RB-9043-P1; Thermo Fisher Scientific) and cleaved
caspase-3 ([CC3]; 9661; Cell Signaling Technology). Briefly, sections of the samples
were deparaffinized sequentially in xylene and decreasing concentrations of ethanol prior
to rehydration and transfer to PBS. For CC3 antigen retrieval from the slides were placed
in a steamer (Hamilton Beach) in sodium citrate (pH 6) buffer for 25 minutes. Antigen
retrieval for staining for Ki67 was performed in Diva Decloaker solution (#DV2004MX;
Biocare Medical). Endogenous tissue peroxidase activity was quenched with 3%
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hydrogen peroxide in 100% methanol for 12 minutes. Slides were then washed and
blocked with 5% goat serum in PBS for 1 hour at room temperature. A primary antibody
was then diluted in 5% goat serum in PBS overnight at 4°C in a humidified chamber.
Ki67 was diluted at 1:200, whereas CC3 was diluted at 1:100. Slides were then washed
three times with PBS. CC3 stained slides were incubated with a biotinylated anti-rabbit
antibody (#GR602H; Biocare Medical) for 20 minutes at room temperature. Next, slides
were washed three more times with PBS and incubated for 20 minutes with a
streptavidin-horseradish peroxidase label (#HP604H; Biocare Medicare). For Ki67
staining, slides were incubated with a secondary anti-rabbit antibody conjugated to
horseradish peroxidase (#111-036-047; Jackson ImmunoResearch) diluted in 5% goat
serum in PBS at a 1:500 dilution for 1 hour at room temperature. CD31 staining of frozen
sections was also performed. Sections were fixed in cold acetone for 15 minutes, washed
with PBS, blocked with 5% goat serum in PBS, and incubated with a rat monoclonal antimouse CD31 antibody (1:200, 553370; Pharmingen) overnight at 4°C. The next day,
slides were washed with PBS, and an appropriate horseradish peroxidase-conjugated
secondary antibody was placed on them for 1 hour at room temperature. After secondary
antibody incubation, slides were again washed with PBS, briefly washed with PBS
containing Brij 35 (#858366; Sigma-Aldrich), and placed in 3,3'-diaminobenzidine
(#750118; Thermo Fisher Scientific). Upon color change, slides were rinsed in Milli-Q
water and counterstained with hematoxylin (#GHS316; Sigma-Aldrich) for 13 seconds,
rinsed in water again, and left to dry. Slides were then mounted with coverslips using
Permount medium (#SP15-100; Thermo Fisher Scientific). Slides were imaged using a
Leica DM4000 B LED microscope. For quantification of tumor specimens five random
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high-power field (HPF) photographs of each slide were taken, and stained cells were
counted manually.

3.6 EdU incorporation assay, annexin V staining, and cell-cycle assay
Ovarian cancer cells were plated in technical duplicates per experiment in six-well
plates at a density of 50,000-100,000 cells per well. The next day, cells were transfected
with siRNA as described above. SiGrb2 and siControl cells were harvested 72 hours
after transfection. Harvested cells were then pulsed with EdU for 2 hours and processed
using a Click-iT Plus EdU Alexa Fluor 488 Flow Cytometry Assay Kit (#C10632; Thermo
Fisher Scientific) following the manufacturer’s protocol. For annexin V staining ovarian
cancer cells after transfection a BD Biosciences FITC Annexin V Apoptosis Detection Kit
I (#556547) was used according to the manufacturer’s protocol. After annexin V analysis,
cells were stained with 4’,6-diamidino-2-phenylindol) for use in cell-cycle analysis. For
flow cytometric analysis and data collection a Beckman Coulter Gallios Flow Cytometer
was used.

3.7 Colony formation assay
Ovarian cancer cells were plated in technical duplicates per experiment in six-well
plates at a density of 1000 cells per well. Twenty-four hours after seeding, cells were
transfected with either siControl or siGrb2 using methods described previously. Cells
were left to grow in a tissue culture incubator for 7-10 days. Afterward, the cells were
washed two times with ice-cold PBS and fixed with ice-cold 100% methanol for 10
minutes. After 10 minutes, the methanol was discarded, and the cells were stained with
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a crystal violet solution (0.5% crystal violet with 20% methanol in Milli-Q water; SigmaAldrich) for 10 minutes at room temperature. Crystal violet was then removed, and the
cells were washed with deionized Milli-Q water three times and left to dry at room
temperature.

3.8 Invasion assay
Invasion assays were performed using a Transwell system (8-m pore size;
Corning Inc.). Briefly, 24 and 48 hours after siRNA transfection of Grb2 and control
siRNA, cells were harvested and quantified. Next, 3 x 105 cells were seeded onto the
apical side of a Transwell chamber pre-coated with Matrigel (six-well insert) in serumdeprived culture Media supplemented with 10% FBS was added to the basal
compartment of the chamber to serve as a chemoattractant. The cells were allowed to
migrate from top chamber to bottom chamber overnight for 24 hours and then fixed. The
cells that remained on the apical side of the chamber were gently scraped off with cotton
swabs. The invading cells were then quantified.

3.9 Tube formation assay
RF-24 endothelial cells were plated on six-well plates at a density of 100,000 cells
per well and allowed to attach overnight. The cells were transfected with siControl or
siGrb2 at 24 hours. After 72 hours, cells were harvested and counted. A µ-plate for use
in an angiogenesis assay was then coated with 10 L of Matrigel, which was allowed to
solidify at 37°C for 1 hour. Next, 20,000 cells per well were seeded on the Matrigel. The
cells were incubated at 37°C for 6 hours. To assess endothelial cell tube formation, we
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counted and photographed complete tubes in randomly chosen fields at 40x
magnification using an Olympus inverted microscope connected to a digital camera.

3.10 Ex-vivo NMR metabolomics
Excised tumor tissue samples were flash frozen, weighed and crushed into fine powder
in liquid nitrogen environment. These were immersed in 3 mL of methanol-to-water
solution (2:1) and vortexed in presence of polymer beads. A rigorous process of
mechanical homogenization was followed by centrifugation of the solution for ten minutes
to separate the water-soluble metabolites from proteins and other cellular constituents.
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Rotary evaporation method was used for the supernatant to remove the methanol. A

lyophilizer was used to dry the sample out and collect the metabolites. The water soluble
metabolites were finally dissolved in a solution of 600 μL of 2H 20, 36 μL of PO4 buffer,
and 4 μL of 80 mM DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid). Phosphate buffer
was added to stabilize the pH variations, and DSS was served as the reference standard
to normalize the spectroscopic NMR signal of each metabolite.

60

NMR spectrum of each sample was obtained using a Bruker AVANCE III HD® NMR
scanner (Bruker Bio Spin Corporation, at room temperature The operating frequency of
the NMR spectrometer for proton resonance was 500 MHz and it was endowed with a
triple resonance (1H,

13C, 15N)

cryogenic temperature probe with a Z-axis shielded

gradient. Water suppression sequence was employed using a pre-saturation technique
of the RF pulse. Spectroscopic data were obtained with a 90º pulse width flowed a scan
delay trel of 6.0 s, a 1024 Hz spectral width. The time domain NMR signal was acquired
using an exponential function. After the final spectrum was acquired the phase correction
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was performed. The analysis of the metabolomics data was carried out using Chenomx
NMR Suite 8.1 software (Chenomx Inc., Edmonton, Canada). Quantitative analysis of
the metabolites was then performed using MestReNova software (Mestrelab Research,
Spain) by integrating the resonance peak for each metabolite. Finally the integral value
was normalized by the value of the integral of the DSS resonance peak.

3.11 Reverse phase protein array and pathway analysis
A reverse phase protein array (RPPA) assay was carried out by the MD Anderson
Functional Proteomics Reverse Phase Protein Array (RPPA) Core. OVCAR8 cells were
treated with siControl or siGrb2 for 72 hours. Cell lysates were then collected in RIPA
buffer containing freshly added protease and phosphatase inhibitors. Protein
concentrations were quantified using a BCA assay kit (Pierce Biotechnology), and 45 g
of protein from each group was used for RPPA analysis with a validated set of antibodies.
To determine the biological function of Grb2, protein expression changes after siRNA
transfection were used for pathway analysis with Ingenuity Pathway Analysis software
and Netwalker pathway analysis software. The comparison analysis between siControltreated cells and siGrb2-treated cells was carried out in R (version 3.5.1). Normalized
data was at first log2 transformed (log2(x+1)). Differential expressed proteins between
the two groups were identified by a p-value, obtained from the moderated t-statistic from
LIMMA package, of less than 0.05. To support visual data exploration, a heatmap for the
most significant cases was generated using the heatmap.2 function from the gplots
package.
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3.12 Statistical analysis
The Student t-test (for comparison of two groups) and ANOVA (for comparison of
all groups) were used to calculate P values for normally distributed data. Network and
pathway analyses were performed using the NetWalker network analysis (version 1.0)
and Ingenuity Pathway Analysis software programs. All statistical data were analyzed
using the Prism software program (GraphPad Software). P values less than 0.05
according to two-tailed tests were considered significant. When multiple tests were
performed, the BUM (beta uniform mixture) model
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was used to fit p-values and

estimate counts of significant features at different FDRs. All statistical tests were twosided unless otherwise noted.
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4. Results
4.1 Therapeutic Efficacy of L-Grb2 in Orthotopic models of ovarian cancer
We first performed an L-Grb2 dose-finding experiment using a murine ovarian cancer
model (OVCAR5) and measured Grb2 protein expression in harvested tumors at 24 and
72 hours after L-Grb2 administration. Grb2 protein expression was reduced in tumors for
up to 72 hours after injection of 15 and 25 mg/kg L-Grb2 (Figure 4). Next, we examined
the effects of 15 and 25 mg/kg L-Grb2 on tumor growth in vivo using the OVCAR5 model.
After intraperitoneal injection of OVCAR5 cells, we gave mice L-Grb2 twice weekly. We
observed a reduction in tumor growth at 15 mg/kg, but there was no additive benefit of
increasing the L-Grb2 dose beyond that. We also saw a reduced number of nodules after
treatment with 15 mg/kg L-Grb2. Weight loss did not differ markedly among the treatment
groups (Figure 4B-E). First line chemotherapy in ovarian cancer patients includes
platinum- and taxane- based therapy. Since taxanes have combined well with biologically
targeted drugs, we first performed a series of experiments to characterize the therapeutic
efficacy of L-Grb2 in combination with paclitaxel. In the OVCAR5 model, tumor growth
was significantly lower in mice given L-Grb2 and paclitaxel (0.17 g ± 0.10 g) than in
control mice (0.99 g ± 0.35 g) (Figure 5A). We noted a decrease in tumor growth in the
mice given L-Grb2 only, as well (0.29 g ± 0.14 g). We observed fewer metastatic nodules
in mice given L-Grb2 only or combined with paclitaxel than in control mice given an empty
DOPC liposome (L-Grb2 only, 5.9 ± 2.9; L-Grb2 and paclitaxel, 2.00 ± 0.72; control, 9.2
± 2.5) (Figure 5B). We noted no changes in mouse weight and no noticeable changes
in mouse mobility during treatment with L-Grb2 (Figure 4E).
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Figure 4. Results of an L-Grb2 dose-defining experiment to evaluate ovarian tumor
growth. A, Western blot analysis of Grb2 protein expression in tumors obtained from
mice inoculated with OVCAR5 cells 24 and 72 hours after the last intravenous injection
of an empty DOPC liposome (control [Con]), 10 mg/kg L-Grb2, 15 mg/kg L-Grb2, or 25
mg/kg L-Grb2. B-D, Mean body weights of (B), tumor weights in (C), and numbers of
metastatic nodules in (D) mice intraperitoneally inoculated with OVCAR5 cells (n = 10
per group). Mice received treatment with L-Grb2 at 15 and 25 mg/kg twice weekly. E,
Mean body weights of mice inoculated with OVCAR5 cells that received control
treatment, paclitaxel only (3 mg/kg) weekly, L-Grb2 only (15 mg/kg) twice weekly, or a
combination of L-Grb2 and paclitaxel beginning 10 days after inoculation (n = 9 mice per
group). Error bars, SEM. All statistical tests were two-sided. Asterisk indicates statistical
significant of ***p<0.001, **p<0.01, *p<0.05. NS indicates non-significant.
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Figure 5. Effects of treatment with L-Grb2 on ovarian tumor growth. A and B, Mean
tumor weights (A) and numbers of metastatic nodules (B) in mice intraperitoneally
inoculated with OVCAR5 cells that received an empty DOPC liposome (control),
paclitaxel only (3 mg/kg) weekly, L-Grb2 (15 mg/kg) twice weekly, or a combination of LGrb2 and paclitaxel beginning 10 days after inoculation (n = 9 mice per group). C and D,
Tumors collected from the mice at the conclusion of in vivo therapeutic experiments and
tumors were examined using immunohistochemical staining to evaluate the effects of
treatment with L-Grb2, paclitaxel, or both in comparison with those of the control
treatment on (C) cell proliferation (Ki67 staining) and (D) apoptosis (CC3 staining).
Representative images of mice from the four groups taken at 20x magnification are
shown at the upper right. The mean numbers of Ki67+ and CC3 + cells per group are
shown in the adjoining graphs. Five tumors per group were stained, and five
representative images per sample were quantified were used for analysis. Error bars,
SEM. All statistical tests were two-sided. Asterisk indicates statistical significant of
***p<0.001, **p<0.01, *p<0.05. NS indicates non-significant.
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4.2 Biological effects of L-Grb2 on proliferation and apoptosis
Ovarian tumors harvested from mice in our in vivo experiments were then stained for
markers of proliferation (Ki67) and apoptosis (CC3). In the OVCAR5 model, treatment
with the combination of L-Grb2 and paclitaxel resulted in the greatest reduction of cellular
proliferation as determined via Ki67 staining (mean, 73.50 Ki67+ cells per HPF). In
comparison, the mean numbers of Ki67+ cells per HPF were 102.40 in the control group,
89.43 in the paclitaxel-alone group, and 99.95 in the L-Grb2–alone group (Figure 5C).
In addition, we saw more CC3+ cells in the L-Grb2–alone (mean, 62.82 CC3+ cells per
HPF) and combination L-Grb2 and paclitaxel (mean, 60.55 CC3+ cells per HPF) groups
than in the control (mean, 29.95 CC3+ cells per HPF) and paclitaxel-alone (mean, 49.30
CC3+ cells per HPF) groups (Figure 5D). The reduction in number of proliferative cells
and increase in that of apoptotic cells were significant in the combination group compared
to control groups.

4.3 Effect of Grb2 downregulation in ovarian cancer cell lines in vitro
We measured the baseline expression of Grb2 in a panel of seven ovarian cancer cell
lines and compared it with that in the non-transformed ovarian cell line HIO180 (Figure
6A). We then transfected the cells with 100nm of siControl or siGrb2 to downregulate
Grb2 protein expression (Figure 6B). After observing decreased protein expression of
Grb2 in all cell lines, we assessed the effect of Grb2 downregulation on three cell lines
with high Grb2 protein expression (OVCAR8, OVCAR5, and SKOV3ip1) and two with
low Grb2 protein expression (HEYA8 and A2780) using a cell viability assay. OVCAR8
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and SKOV3ip1 were the most sensitive to Grb2 downregulation (Figure 6C and D). We
characterized the cell lines according to their mutation status and found that cell lines
with ErbB2 mutations or amplifications were the most sensitive to Grb2 downregulation
(Table 3). Increased ErbB2 protein expression was confirmed on Western blot analysis
(Figure 6E).
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Figure 6. Effect of Grb2 downregulation on ovarian cancer cell lines. A, Western blot
analysis of Grb2 expression in a panel of ovarian cancer cell lines compared with that in
the non-transformed epithelial ovarian cell line HIO180. The adjoining graph shows their
expression compared with that in HIO180. B, Western blot analysis of Grb2 expression
in OVCAR8 cells 72 hours after siGrb2 transfection compared with that in untreated (UT)
and siControl-transfected (Con siRNA) cells. C, OVCAR8, SKOV3ip1, A2780, HEYA8,
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and OVCAR5 cell lines were transfected with siGrb2 or siControl at increasing
concentrations. An alamarBlue assay of the cells was performed 72 hours after
transfection to determine their percent viability, which is shown in the graphs. The data
represent averages of triplicate measurements. D, The percent viability of the five cell
lines in C 72 hours after transfection of siGrb2 and siControl at 160 nM. E, Western Blot
analysis of ErbB2 expression in a panel of ovarian cancer cell lines compared to fallopian
tubal epithelium (FTE) F, Results of an annexin V assay performed to determine the
number of apoptotic untreated (UT), siControl-transfected (100 nM), and siGrb2transfected (100 nM) ovarian cancer cells. The assay was performed 72 hours after
transfection. Error bars, SEM. All statistical tests were two-sided. Asterisk indicates
statistical significant of ***p<0.001, **p<0.01, *p<0.05. NS indicates non-significant.

Table 3. Mutation statuses of the ovarian cancer cell lines used in the study 62,63
Gene
Cell line

ErbB2

PIK3CA

PTEN

KRAS

BRAF

OVCAR-8

Mut

WT

WT

Mut

WT

A2780

WT

Mut

Mut

WT

Mut

p.E365K

p.KGR128del

WT

WT

Mut

WT

OVCAR-5

WT

pG12V
HeyA8

WT

WT

WT

Mut

Mut

SKOV3ip1

Amp

Mut

WT

WT

WT

p.H1047R
Abbreviations: Amp, amplification; Mut, mutant; WT, wild-type.

Because of the inhibition of ovarian tumor growth and increased apoptosis in in vivo
tumor specimens, we next examined the in vitro effects of Grb2 downregulation by siRNA
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on the ovarian cancer cell lines described above. An annexin V assay demonstrated an
increase in apoptosis after Grb2 downregulation in all cell lines, with the greatest effects
seen in the OVCAR8 cells (siGrb2, 33.0% apoptotic; untreated, 7.3% apoptotic) and
SKOV3ip1 cells (siGrb2, 17.69% apoptotic; untreated, 6.41% apoptotic) (Figure 6F).
Next, we examined the effect of Grb2 downregulation on ovarian cancer cell proliferation.
We observed no effect on the number of proliferative OVCAR8 cells at 72 hours
(siControl, 34.95 ± 0.94; siGrb2, 37.94 ± 1.54) (Figure 7A). We also observed no change
in the number of colonies formed in OVCAR5 cells in a colony formation assay (siControl,
848 ± 53; siGrb2, 1014 ± 121). However, the quantified colonies were smaller in the
siGrb2-exposed group than in the controls (mean ± SEM colony area: siGrb2, 1.290 ±
0.175 mm2; siControl, 2.45 ± 0.50 mm2) (Figure 7B). These results corroborated our in
vivo findings that Grb2 downregulation due to treatment with L-Grb2 leads to an increase
in the number of apoptotic cells. We found no effects of Grb2 downregulation on cellcycle progression (Figure 8A). Finally, we performed an invasion assay using OVCAR8
cancer cells at varying time points. At 72 hours after transfection we found cells treated
with siGrb2 were largely apoptotic. At 48 hours, cells treated with siGrb2 were found to
have no effect on invasive potential (Figure 8B).
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Figure 7. Effect of Grb2 downregulation on ovarian cancer cell proliferation. A, Results
of an EdU incorporation assay performed to determine the number of proliferative
untreated, siControl-treated (con), and siGrb2 treated OVCAR8 cells (72 hours after
treatment). B, Results of a colony formation assay of the OVCAR5 cell line. After siRNAbased treatment, cell colonies were allowed to grow for 7-10 days before quantification.
The adjoining graph shows the mean ± SEM total number of colonies and area of
colonies in the three groups. Asterisk indicates statistical significant of ***p<0.001,
**p<0.01, *p<0.05. NS indicates non-significant.
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Figure 8. Effect of Grb2 downregulation on cell-cycle progression and invasion in ovarian
cancer cells. A, Results of a cell-cycle assay performed using untreated, siControltreated, and siGrb2-treated OVCAR8, SKOV3ip1, HEYA8, and OVCAR5 cells at 72
hours after transfection. B, Results of a Matrigel invasion assay performed 48 and 72
hours after transfection of OVCAR8 ovarian cancer cells with siControl or siGrb2. At 72
hours, cells were apoptotic, and quantification of invading cells was not performed. The
adjoining graph shows the corresponding mean numbers of invasive cells 48 hours after
transfection. Error bars, SEM. All statistical tests were two-sided. Asterisk indicates
statistical significant of ***p<0.001, **p<0.01, *p<0.05. NS indicates non-significant.
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4.4 Pathway analysis after Grb2 downregulation on ovarian cancer cell lines
Next, to understand the broader downstream effects of Grb2 inhibition on ovarian cancer
cell lines we conducted an RPPA analysis with OVCAR8 cells (Figure 9A). To identify
pathways in these cells affected by Grb2 downregulation after transfection with siGrb2,
we used the NetWalker software program (Figure 9B). Networks significantly affected
by Grb2 downregulation included Generation of precursor metabolites and energy
(downregulated) and Negative regulation of apoptosis (downregulated) (Table 4).
Additionally, there was downregulation of insulin receptor signaling (Table 4) and
glycolytic metabolites (Figure 9C). We confirmed the protein expression of glycolytic
enzymes and marker of mitochondrial stress, superoxide dismutase 2 (SOD2), by
Western blot (Figure 9D). It is well documented that rapidly proliferating tumor cells rely
on aerobic glycolysis in a phenomenon referred to as the Warburg effect

64-66.

Deregulated c-MYC, HIF1a and growth signaling lead to induction of glycolytic enzymes
and inhibition of pyruvate oxidation in mitochondria

67-69.

Disrupting the Warburg effect

to shunt cancer metabolism to oxidative phosphorylation, subsequently increases
oxidative stress triggering apoptosis

70-72.

Therefore, based on our RPPA and pathway

analysis we hypothesized Grb2 downregulation was leading to a disruption in the
Warburg effect, shunting metabolism to the tricarboxylic acid (TCA) cycle. To confirm
this, we performed metabolomic analysis of OVCAR8 cells with Grb2 downregulation.
Specifically, we compared the metabolite levels in OVCAR8 cells transfected with
siControl to those cells transfected with siGrb2. We analyzed a total of 295 metabolites
and found that 61 of them were significantly dysregulated after Grb2 downregulation
(Figure 10A). We then performed metabolite set enrichment analysis of the relative
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concentrations of metabolites with significant differences between OVCAR8 cells with
Grb2 downregulation and control cells to identify biological patterns (Figure 10B).
Additionally, we used the metabolomic pathway analysis module of the MetaboAnalyst
software program to identify the pathways most affected by Grb2 downregulation.
Dysregulated metabolites lead to enrichment of amino acid metabolism and the TCA
cycle (Figure 11A). Because pathway analysis could only provide associations between
metabolites and pathway regulation, we went back to our original data to quantify
metabolites specific to the TCA cycle. We found an increase in TCA intermediates,
fumurate, malate, succinate, isocitrate, succinyl-coA and oxaloacetate in cells
transfected with siGrb2 (Figure 11B). Finally, we corroborated these results with our
harvested in vivo tumors through NMR spectroscopy. After tumors were analyzed,
metabolite levels between L-Grb2 and empty DOPC treated tumors were compared. We
found substantially lower lactate and choline levels in the L-Grb2 monotherapy group of
tumors harvested than in the control group (Figure 11C, Figure 12). Based on these
findings we concluded that Grb2 downregulation leads to a disruption of the Warburg
effect though a decrease in LDHA. This subsequently increases oxidative
phosphorylation, and mitochondrial stress as seen through an increase in SOD2.
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Figure 9. Differential expression of proteins OVCAR8 ovarian cancer cells after Grb2
downregulation as detected using an RPPA. A, Heat map of proteins whose expression
differed significantly between siGrb2- and siControl-transfected groups (P < 0.05). B,
Networks generated after Grb2 downregulation using NetWalker software. Fold changes
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in protein expression were calculated on the basis of NormLog2 expression differences
between the siControl- and siGrb2-transfected cells. C, Heat map of glycolytic enzymes
whose expression differed between siGrb2- and siControl-transfected groups (P<0.05).
D, Western blot analysis of glycolytic enzymes after siGrb2 transfection.

Table 4. The networks most affected by Grb2 downregulation in ovarian cancer cells
Network
Cellular

Effect
response

to Downregulated

Number of occurrences*
10

hormone stimulus
Response

to

insulin Downregulated

9

stimulus
Negative

regulation

of Downregulated

8

precursor Downregulated

7

apoptosis
Generation of

metabolites and energy
Regulation

of

leukocyte Upregulated

10

Hematopoiesis

Upregulated

10

T-cell activation

Upregulated

7

kinase Upregulated

7

activation

Regulation

of

activity
*The number of molecules significantly associated with the network.
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Figure 10. Effect of Grb2 downregulation on metabolite levels in ovarian cancer cells.
OVCAR8 ovarian cancer cells harvested after control and Grb2 siRNA transfection. Cells
then underwent mass spectroscopy for quantification of metabolites. A, Heatmap of 61
metabolites differentially expressed after Grb2 siRNA transfection. B, Pathways
overrepresented in differentially expressed metabolites in siGrb2-transfected but not in
siControl-transfected ovarian cancer cells. Metabolite set enrichment analysis was
performed using the MetaboAnalyst software program.
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Figure 11. Effect of Grb2 downregulation on metabolite levels in ovarian cancer cells. A,
Metabolites analyzed using the pathway analysis module of MetaboAnalyst. TCA,
tricarboxylic acid; tRNA, transfer RNA. B, TCA metabolite levels in OVCAR8 ovarian
cancer cells after siGrb2 and siControl transfection. C, Effect of Grb2 downregulation on
lactate and choline levels in ovarian tumors. Mass spectroscopy was used to quantify
metabolite levels in OVCAR5 tumors collected at the conclusion of an in vivo therapeutic
experiment from control mice and mice given L-Grb2–based monotherapy (n = 5). Error
bars, SEM. All statistical tests were two-sided. Asterisk indicates statistical significant
of ***p<0.001, **p<0.01, *p<0.05. NS indicates non-significant.
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Figure 12. Effect of Grb2 downregulation on mean metabolite levels in ovarian tumors.
Mass spectroscopy was used to quantify metabolite levels in OVCAR5 tumors collected
at the conclusion of an in vivo therapeutic experiment from control mice and mice given
L-Grb2–based monotherapy (n = 5). Error bars, SEM. All statistical tests were two-sided.
Asterisk indicates statistical significant of ***p<0.001, **p<0.01, *p<0.05. NS indicates
non-significant.

4.5 Anti-angiogenic effects of L-Grb2 and B-20 in ovarian tumors
The vascular endothelial growth factor (VEGF) signaling pathway plays a pivotal role in
angiogenesis, thus several strategies have been designed to target VEGF signal
transduction

73,74.

The effects of VEGF are mediated by two receptor tyrosine kinases,

VEGFR-1 and VEGFR-2, which require Grb2 for signaling

75.

To investigate the

relationship between Grb2 and angiogenesis through VEGF signaling we examined
TCGA tumor mRNA expression. We found Grb2 expression correlates strongly with
VEGFR-1 (R=0.61, P<0.001), VEGFR-2 (R=0.62, P<0.001), expression and proangiogenic genes E-Cadherin (R=0.51, P<0.001), and PECAM1 (R=0.75, P<0.001),
(Figure 13A). Given these findings, we hypothesized that Grb2 downregulation may lead
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to a decrease in angiogenesis and thus work well with anti-angiogenic therapy. To test
this, we performed a cell viability assay and found a decrease in the number of viable
RF-24 endothelial cells after Grb2 downregulation (Figure 13B). We then tested the
effect of Grb2 downregulation on RF-24 cells in vitro using an endothelial cell tube
formation assay (Figure 13C). We observed a decrease in endothelial cell viability with
Grb2 downregulation and a corresponding decrease in the number of tubes formed by
RF-24 cells (mean [± SEM], 19 ± 1 tubes for siGrb2-transfected cells and 76 ± 6 tubes
for siControl-transfected cells).
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Figure 13. A. TCGA tumor mRNA seq expression data. Correlation between Grb2
expression and VEGFR1 (FLT1), VEGFR2 (KDR), PECAM1 and E-Cadherin (CDH1).
B-C. In vitro effects of Grb2 downregulation on endothelial cells. B, Results of an
alamarBlue viability assay performed to determine the sensitivity of siGrb2-transfected
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RF-24 endothelial cells to Grb2 downregulation versus that of siControl-transfected RF24 cells. The assay was performed 72 hours after transfection. The data represent the
average values from triplicate measurements. C, Left: the mean numbers of tubes
formed by RF-24 cells on a gel matrix (n = 3 wells per group; mean number of tubes
quantified using five pictures per well). Right: representative images of endothelial vessel
formation of by RF-24 cells after transfection with siGrb2 or siControl. Images were taken
at 40x magnification. Error bars, SEM. All statistical tests were two-sided. Asterisk
indicates statistical significant of ***p<0.001, **p<0.01, *p<0.05. NS indicates nonsignificant.

Next, we evaluated the effects of L-Grb2 on angiogenesis in vivo. First, we investigated
the effects of treatment with L-Grb2 in combination with B-20 in SKOV3ip1 cells. We also
observed substantial reductions in tumor weight in all groups of mice, with a 86%
decrease in tumor weight in mice given the combination of L-Grb2 and B-20 (mean ±
SEM, 0.16 g ± 0.05 g versus 1.21 g ± 0.49 g in the control group). The number of tumor
nodules was decreased in all groups. We also saw no significant differences in mouse
weights in the treatment groups (Figure 14A-C). We then stained tumors harvested from
the study mice for the vessel marker CD31. We found decreases in the number of vessels
in all treatment groups, as the mean (± SEM) vessel numbers were 26.97 ± 3.37 in the
control group, 11.28 ± 1.29 in the B-20–only group, 18.67 ± 2.84 in the L-Grb2–only
group, and 10.38 ± 1.19 in the combination L-Grb2 and B-20 group (Figure 14D). We
also stained OVCAR-5 tumor sections for CD31 and found a significantly lower mean (±
SEM) number of vessels in mice given the combination of L-Grb2 and paclitaxel (34.11
± 3.46) than in the L-Grb2–only (24.88 ± 3.88), control (33.33 ± 3.25), and paclitaxel-only
(33.33 ± 3.25) groups (Figure 14D).
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Figure 14. In vivo effects of treatment with L-Grb2 in combination with antiangiogenic
therapy in an ovarian tumor model. A-C, Mean tumor weights in (A), numbers of
metastatic nodules in (B), and body weights of (C) mice intraperitoneally inoculated with
SKOV3ip1 cells that received control treatment, B-20 only (15 mg/kg) twice weekly, LGrb2 only (15 mg/kg) twice weekly, or a combination of B-20 and L-Grb2 beginning 10
days after inoculation (n = 9 mice per group). D, Tumors collected from the SKOV3ip1
and OVCAR5 models at the conclusion of in vivo therapeutic experiments were subjected
to immunohistochemical staining for CD31 to evaluate the effects on tumor vessel
number of treatment with L-Grb2, B-20, or both compared with the control treatment.
Representative staining images taken at 20x magnification are shown. The mean CD31+
cell numbers per group are shown in the adjoining graphs. Five tumors per group were
stained, and five representative images per sample were quantified for analysis. Error
bars, SEM. All statistical tests were two-sided. Asterisk indicates statistical significant of
***p<0.001, **p<0.01, *p<0.05. NS indicates non-significant.
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4.6 Effect of Grb2 downregulation in uterine cancer cell lines in vitro
Next, we sought to determine the role of Grb2 in uterine cancer cell lines. Uterine
carcinoma is the leading gynecologic malignancy in the United States, for which the
number of available therapies is limited.

76

Molecular characterization of endometrial

tumors has demonstrated that PIK3CA mutations, PTEN loss, and PI3K and KRAS
activation are key events in carcinogenesis.

77,78

In addition to these critical mutations,

ErbB2 is amplified in 17-33% of carcinosarcoma, and uterine serous carcinomas.

79,80

Given our findings in ErbB2 mutated or amplified ovarian cancer cell lines, we
hypothesized that Grb2 was a critical mediator of oncogenic signaling in uterine
carcinomas as well. To assess this, we first performed baseline expression of Grb2
protein expression in a panel of uterine cancer models (Figure 15A). We focused on
uterine cell line Hec1a known to have erbB2 amplification. Cell viability assay on Hec1a
verified sensitivity to Grb2 downregulation compared to control siRNA (Figure 15B).
Finally we performed RPPA on Hec1a cells transfected with siControl and siGrb2 (Figure
15C). Networks significantly downregulated after siGrb2 transfection include AMPK
signaling, PI3K/AKT signaling and Insulin Receptor signaling (Figure 15D).
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Figure 15. Effect of Grb2 downregulation on uterine cancer cell lines. A, Western blot
analysis of Grb2 expression in a panel of uterine cancer cell lines. B, An alamarBlue
assay of Hec1a uterine cancer cells performed 72 hours after transfection to determine
their percent viability. Data represent averages of triplicate measurements. C, Differential
expression of proteins in Hec1A cells after Grb2 downregulation as detected using an
RPPA. Heat map of proteins whose expression differed significantly between siGrb2 and
siControl transfected groups, p<0.05. D, Top canonical pathways generated after Grb2
downregulation using Ingenuity Pathway Analysis (IPA). All statistical tests were twosided. Asterisk indicates statistical significant of ***p<0.001, **p<0.01, *p<0.05. NS
indicates non-significant.
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5. Discussion
The key findings form our study include the therapeutic efficacy of L-Grb2 in ovarian
preclinical models by increasing cellular apoptosis, and reducing angiogenesis. Additive
anti-tumor effects were observed in ovarian tumor models treated with L-Grb2 and
paclitaxel. Additionally, L-Grb2 potentiated the effects of anti-angiogenic therapy, B-20,
in ovarian models. Finally, we identified cells lines with ErbB2 mutation or overexpression
to be particularly sensitive to Grb2 downregulation. This correlated to a decrease in
metabolites related to glycolysis and protein synthesis in cell lines after Grb2 inhibition
or L-Grb2 treatment.

5.1 Translational Relevance
Targeting Grb2 protein expression through L-Grb2 is a promising molecular therapy of a
previously thought to be undruggable target. Given the heterogeneity and large number
of molecular alterations in ovarian cancer identifying targets that are of therapeutic
benefit is challenging. However, the use of molecular pathways to develop small
molecule inhibitors, and personalize individual strategies for treatment remains a
promising avenue to improve survival. Grb2 plays a central role in RTK signaling,
particularly EGFR and HER2. Approximately 11% of ovarian tumors overexpress HER2,
while EGFR overexpression can be as high as 28% and amplified in up to 20% of ovarian
cancer patients.

15,81,82

More importantly overexpression of EGFR and ErbB2 has been

associated with poor survival prognosis in gynecologic cancer patients.83 This is likely
due to their association with the Ras/Raf/MAPK and PI3K/PTEN/AKT/mTOR pathways,
which are activated in 70% and 50% of ovarian cancers, respectively.15 The high
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prevalence of these molecular alterations in ovarian cancer represent an important
therapeutic opportunity for L-Grb2.

Given the high rate of reoccurrence and poor prognosis of ovarian cancer, there remains
a need for additional lines of therapy that may increase survival but not necessarily be
curative. Current targeted and biologic therapies in development or in use in ovarian
cancer include antiangiogenic agents, poly (ADP-ribose) polymerase (PARP) inhibitors,
immunotherapy, and small molecule inhibitors of signaling pathways. While currently
only bevacizumab and PARP inhibitors are FDA-approved as targeted therapy for
ovarian cancer patients, the number of small molecule inhibitors in clinical development
is growing. As previously mentioned MAPK and PI3K/AKT/mTOR pathways are
important cellular signaling pathways involved in proliferation, tumorigenesis, cell
survival, angiogenesis, and protein synthesis. Small molecular inhibitors including
temsirolimus (TOR complex 1 inhibitor), Pictilisib (PI3K inhibitor), and selumetinib (MEK
inhibitor) have had varying efficacy in ovarian cancer patients. These pathways converge
at several points, therefore dual blockade or upstream blockade of these pathways may
provide synergistic effects and overcome tumor resistance.

The clinical activity of L-Grb2 was recently assessed in a phase 1 trial (BP1001, Bio-Path
Holdings) in patients with refractory or relapsed acute myeloid leukemia. Targeting Grb2
is particularly promising in leukemia given the number of activating mutations of tyrosine
kinases. BP1001 was well tolerated with anti-leukemic activity as monotherapy and in
combination with cytarabine. A maximum tolerated dose was not identified, and the most
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common grade 3-4 adverse events were cardiopulmonary disorders (25 [64%] of 39
patients), fever and infections (17 [44%]).84 Enrollment for a phase 2 study of patients
with previously untreated acute myeloid leukemia is underway.

5.2 Study Limitations
Here we show that L-Grb2 has promising activity in preclinical models of ovarian
carcinoma. While evidence of L-Grb2 antitumor activity in hematologic malignancies is
promising, it is yet to be seen if this can be translated to solid tumors. Additionally therapy
targeting erbB2 receptor have had limited success. Another limitation to this work is that
only orthotopic ovarian models were investigated, patient derived xenograft models
should be considered for future studies.

5.3 Implications and Future Directions
Our preclinical findings support the idea that Grb2 blockade may be an effective
treatment for ovarian cancers. Future directions for L-Grb2 include administration as an
adjuvant therapy in combination with taxane-based therapy after surgical reduction.
Alternatively, L-Grb2 could combine well with bevazicumab, based on our preclinical
data. Finally, in patients with high erbB2 expression, lower treatment doses could be
considered. Additionally L-Grb2 may prove to be useful in a number of solid malignancies
including uterine carcinoma.
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In summary, this work introduces a therapy, L-Grb2, which may be beneficial to ovarian
cancer patients. Our in vivo studies suggest that combination therapy with paclitaxel and
anti-angiogenics is well tolerated and provides anti-tumor effects.
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